ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,067.00
-1.24%
S&P ASX All Technology
3,766.30
-0.74%
Brent Oil
72.72
0.00%
US Dollar vs AUD
1.59949
0.00%
Bitcoin
97,066.62
-0.14%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Altimmune Inc (ALT) Share Price

Altimmune Inc

Altimmune Inc (ALT)

Analytica Limited
Altitude Group Plc
Alturas Minerals Corp
8.25
0.07
(0.86%)
Closed 22 December 8:00AM
Delayed by 15 minutes
8.40
0.15
(1.82%)
After Hours: 11:56AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
8.40
Bid
7.90
Offer
26.00
Volume
4,694,890
8.18 Day's Range 8.75
5.29 52 Week Range 14.84
Market Cap
597.447M
Previous Close
8.18
Open
8.38
Last Trade
119
@
8.4
(formt)
Last Trade Time
Financial Volume
US$ 39,610,665
VWAP
8.437
Average Volume (3m)
3,051,323
Shares Outstanding
71,124,625
Dividend Yield
-
PE Ratio
-6.64
Earnings Per Share (EPS)
-1.24
Revenue
426k
Net Profit
-88.45M

About Altimmune Inc

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.altimmune.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Altimmune Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALT. The last closing price for Altimmune was US$8.18. Over the last year, Altimmune shares have traded in a share price range of US$ 5.29 to US$ 14.84.

Altimmune currently has 71,124,625 shares in issue. The market capitalisation of Altimmune is US$581.80 million. Altimmune has a price to earnings ratio (PE ratio) of -6.64.

Ask ADVFN Intelligence (AI)

Altimmune (ALT) Options Flow Summary

ALT Options Flow

Overall Flow

Bullish

Net Premium

635k

Calls / Puts

100.00%

Buys / Sells

175.00%

OTM / ITM

1,000.00%

Sweeps Ratio

0.00%

ALT Latest News

More News

Altimmune Added to Nasdaq Biotechnology Index

GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology...

19 December 2024
GlobeNewswire Inc.

Form 8-K - Current report

12 December 2024
Edgar (US Regulatory)

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...

02 December 2024
GlobeNewswire Inc.

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyā€™s management team will...

26 November 2024
GlobeNewswire Inc.

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver MeetingĀ® 2024

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide...

16 November 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

13 November 2024
Edgar (US Regulatory)

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the...

12 November 2024
GlobeNewswire Inc.

Form 8-K - Current report

12 November 2024
Edgar (US Regulatory)

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of...

11 November 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.24-2.777777777788.649.597.704531468418.43158748CS
4-0.01-0.1189060642098.4110.887.704532049778.93518844CS
121.5322.27074235816.8711.165.8630513238.10419261CS
262.542.37288135595.911.165.2931171767.40838119CS
520.374.607721046088.0314.845.2940366108.81771356CS
156-0.85-9.189189189199.2523.492.0929063618.12696262CS
2606.63374.5762711861.7735.11.625156489.78503412CS

ALT - Frequently Asked Questions (FAQ)

What is the current Altimmune share price?
The current share price of Altimmune is US$ 8.40
How many Altimmune shares are in issue?
Altimmune has 71,124,625 shares in issue
What is the market cap of Altimmune?
The market capitalisation of Altimmune is USD 581.8M
What is the 1 year trading range for Altimmune share price?
Altimmune has traded in the range of US$ 5.29 to US$ 14.84 during the past year
What is the PE ratio of Altimmune?
The price to earnings ratio of Altimmune is -6.64
What is the cash to sales ratio of Altimmune?
The cash to sales ratio of Altimmune is 1.38k
What is the reporting currency for Altimmune?
Altimmune reports financial results in USD
What is the latest annual turnover for Altimmune?
The latest annual turnover of Altimmune is USD 426k
What is the latest annual profit for Altimmune?
The latest annual profit of Altimmune is USD -88.45M
What is the registered address of Altimmune?
The registered address for Altimmune is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Altimmune website address?
The website address for Altimmune is www.altimmune.com
Which industry sector does Altimmune operate in?
Altimmune operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.5M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.63M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.84M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
8.58M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
5.96M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

ALT Discussion

View Posts
Mark102 Mark102 3 weeks ago
Still Holding here
As far as buyout and the OS you're looking at roughly 7 billion = 100 a share
10 billion = 140

👍 1
Mark102 Mark102 4 months ago
As promised I don't see any dilution in the filing. Shorts are in trouble
👍 1
Mark102 Mark102 5 months ago
Float is Locked and over 23 million naked shares Short. Shorts have failed Miserably at shaking out Retail and can't cover without a massive loss.
Price Targets
Partner 50 to 75
Buyout 140 to 200
👍 1
Mark102 Mark102 5 months ago
https://forextv.com/top-news/altimmune-announces-publication-of-clinical-study-of-pemvidutide-in-metabolic-dysfunction-associated-steatotic-liver-disease-masld-in-journal-of-hepatology/
👍 1 💯 1
Mark102 Mark102 5 months ago
IT'S HAPPENING
šŸ‘ļø0
Mark102 Mark102 6 months ago
Beautiful Bull Flag
šŸ‘ļø0
girlfriend girlfriend 6 months ago
Well....not quite but a nice pop anyways this week.
šŸ‘ļø0
Mark102 Mark102 6 months ago
Last chance next week above 20
šŸ‘ļø0
Mark102 Mark102 6 months ago
It's being shorted by its competitors not tutes. . An advisor from Lilly is making the presentations of pemvi data this weekend.its what you know not what some want you to believe.
👍 1
brfv11 brfv11 6 months ago
Not a chance at 60. Shorts are playing this one perfectly. Investors are just not interested in ALT. Good luck.
👍 1
Mark102 Mark102 6 months ago
Shorts looking weak and vulnerable today any trading room with the funds could squeeze this to 60 easy
šŸ‘ļø0
Mark102 Mark102 6 months ago
Goldman Sachs been short stacking here for months and they are hosting the fireside tomorrow. I'm loading up today
šŸ‘ļø0
brfv11 brfv11 6 months ago
Time to admit shorty got this one right! This one is going all the way down.
Merger/ buyout what a joke.
šŸ‘ļø0
akamaii akamaii 7 months ago
This Wednesday we hope data rules. Give us data 📈
šŸ‘ļø0
akamaii akamaii 8 months ago
Going long for a year 75 target or 50 plus
šŸ‘ļø0
Mt. Blanc Mt. Blanc 8 months ago
So much for my ALT prediction.

The stock slipped to $7 and may be cratering more since it's getting no love.

Maybe ALT is a $5 stock or lower if buyers aren't interested.

mb
šŸ‘ļø0
Mt. Blanc Mt. Blanc 9 months ago
Radar. ALT $11- $12

Getting picked up.

mb
šŸ‘ļø0
Monksdream Monksdream 9 months ago
ALT over $10
Next day settlement begins 5/28 per SEC mandate
šŸ‘ļø0
Monksdream Monksdream 9 months ago
ALT 10Q due 3/27
Next day settlement begins 5/28
šŸ‘ļø0
saigai saigai 9 months ago
patiently waiting.. for sure something in the way of news is right there and it can only be a plus.. i want the buyout.. let say 4 billion.. 80 bucks a share..gl
šŸ‘ļø0
Mark102 Mark102 9 months ago
Buyout? Partnership? In less than 9 trading days we will find out.
šŸ‘ļø0
Mark102 Mark102 9 months ago
BUCKLE UP. going to break 15 soon
šŸ‘ļø0
saigai saigai 10 months ago
a good read
https://www.rcplondon.ac.uk/news/world-obesity-day-let-s-talk-about-drugs
šŸ‘ļø0
saigai saigai 10 months ago
slow and steady is healthy as the data goes as well.. fast weight loss is never good and the deeper dive into the data im sure will find that Alt has a wider profile a safer profile as it relates to muscle loss and bone density. time will tell...in any case the real value here is the undiscovered uses.. wide profile more mkts...long and strong ...
šŸ‘ļø0
Mt. Blanc Mt. Blanc 10 months ago
ALT @ $12?

Interesting

mb
šŸ‘ļø0
saigai saigai 10 months ago
institutional ownership from nasdaq site
https://www.nasdaq.com/market-activity/stocks/alt/institutional-holdings
šŸ‘ļø0
saigai saigai 10 months ago
big volume wrong direction for now
šŸ‘ļø0
saigai saigai 10 months ago
a good read
https://finance.yahoo.com/news/weight-loss-drugs-patients-lose-134837816.html
šŸ‘ļø0
saigai saigai 11 months ago
and a few more...
šŸ‘ļø0
saigai saigai 11 months ago
you wont be able to chase this..you either in before the news or outside looking in.. patience of a saint..
šŸ‘ļø0
saigai saigai 11 months ago
driving me nutz but i wont sell this until !!!
šŸ‘ļø0
murocman murocman 11 months ago
Post from another board relevant to ALT:

GLP-1 drugs will_be supply-constrained for_a_few_years, according to the NVO and LLY webcasts at JPM. All in-house and CMO capacity suitable for manufacturing injected GLP-1 drugs is already in service. Moreover, the eventual uptake of oral GLP-1 drugs will not ease the manufacturing bottleneck as much as people might think because the low bioavailability of the oral agents requires large amounts of API.
šŸ‘ļø0
AGORDON AGORDON 11 months ago
Altimmune, Inc.
(Nasdaq - ALT) $12/share
Market cap = $644M
Cash = $140M
Cash Burn rate = ($76)/Y
Catalysts:
Pemvidutide - Weight loss drug. Peptide based GLP-1/Glucagon dual receptor agonist. Phase 2 results were respectable. At 48 weeks, for 2.4mg (high dose), weight loss of -15.6% (on the low end of the expected 15-20%)., but comparable to Mounjaro. The TRAEs appear to be less than Mounjaro's. The drug did reduce triglycerides.
HepTCell - an immunotherapeutic for Chronic Hepatitis B. In Phase 2 trials. Next read out could be in April, 2024.
šŸ‘ļø0
Mark102 Mark102 11 months ago
I was wrong ALT is attending the JPM Let's get this deal done.
šŸ‘ļø0
saigai saigai 11 months ago
thanks a lot.. im on a new computer.. id rather have oral surgery than learn a new computer
šŸ‘ļø0
Mark102 Mark102 11 months ago
Data is in check Twitter. Weight loss is a 100 billion market. The results on the liver data show a 100 % reduction of fat at the highest dose. That's a 40 billion market.
Now why is ALT not attending the JPM conference this week? Stay tuned
šŸ‘ļø0
saigai saigai 12 months ago
im hanging around bewteen the two potential mkts for their drug its too crazy to even think out loud lets see what the data says.. if its good or really good. all hell will break out
šŸ‘ļø0
Mark102 Mark102 12 months ago
Float is locked, tutes trying to shake few out but this is a done deal IMO
šŸ‘ļø0
saigai saigai 12 months ago
this is a powder keg...
šŸ‘ļø0
saigai saigai 12 months ago
i believe if they wanted to they could have closed a deal by now but they wait till after the new data.. i wonder why.. there is no way for this to go but way up from here..glta
šŸ‘ļø0
Mark102 Mark102 12 months ago
Been Holding since 6. Buyout or partnership is imminent.
šŸ‘ļø0
1hot toddy 1hot toddy 12 months ago
HUGE BUYS NOW 10K BUY $100K BUY $$$$$$$$$$$$$$$$$$
šŸ‘ļø0
Bud-Wiser Bud-Wiser 12 months ago
Nice comeback today -Iā€™m back in
šŸ‘ļø0
1hot toddy 1hot toddy 12 months ago
WOOOOOOOOOOOW 10K AND 9100 SHARE BUYS 2-$100,000 BUYS $$$$$$$$$$$$$$$$$$$$$$$$$$$$$
BABY MONSTER HERE
šŸ‘ļø0
eyeownu eyeownu 12 months ago
got dammmmmmmmmmm. oprah must be buying out the company
šŸ‘ļø0
1hot toddy 1hot toddy 12 months ago
WOOOOOOW 10,000 SHARE BUY $110,000 BUY $$$$$$$$$$$$$$$$
MONSTER WEIGHT LOSS CO HERE
šŸ‘ļø0
Mark102 Mark102 12 months ago
Next Gap to 19 to fill. PT 60 to 100 on a buyout
šŸ‘ļø0
1hot toddy 1hot toddy 1 year ago
WOOOOOOOOOOOW 21000 SHARE BUY OVER $150,000 BUY . KILLER WEIGHT LOSS HERE $$$$$$$$$$$
šŸ‘ļø0
eyeownu eyeownu 1 year ago
rallys over IMO. end of year.. could be wrong tho!
šŸ‘ļø0
1hot toddy 1hot toddy 1 year ago
WOOOOOOOOOOW 11000 SHARE BUY $90000 BUY WEIGHT LOSS RESULTS GREAT $$$$$
šŸ‘ļø0

Your Recent History

NASDAQ
ALT
Altimmune
DOWI
DJCIP2IT
DJ Commodity Index Plati...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads